Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Thoracic 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Prostatic Neoplasms 21Carcinoma, Non-Small-Cell Lung 21Breast Neoplasms 20Neoplasms 19Stomach Neoplasms 15Colorectal Neoplasms 15Lung Neoplasms 13Endometrial Neoplasms 13Pancreatic Neoplasms 11Leukemia, Myeloid, Acute 10Colonic Neoplasms 9Carcinoma, Hepatocellular 9Oropharyngeal Neoplasms 6Neoplasm Metastasis 6Multiple Myeloma 6Melanoma 6Lymphoma, Large B-Cell, Diffuse 6Esophageal Neoplasms 6Squamous Cell Carcinoma of Head and Neck 5Sarcoma 5Rectal Neoplasms 5Mouth Neoplasms 5Leukemia, Lymphocytic, Chronic, B-Cell 5Head and Neck Neoplasms 5Uterine Cervical Neoplasms 4Recurrence 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Mantle-Cell 4Leukemia, Myelomonocytic, Acute 4Leukemia, Monocytic, Acute 4

Interventions

Carboplatin 7Trastuzumab 6Docetaxel 5pembrolizumab 4Paclitaxel 4Oxaliplatin 4Fluorouracil 4Cytarabine 4Cyclophosphamide 4Azacitidine 4pertuzumab 3Radiotherapy 3Observation 3Neoadjuvant Therapy 3Epirubicin 3Endoscopy 3Cisplatin 3Chemoradiotherapy 3Capecitabine 3venetoclax 2toripalimab 2sargramostim 2olaparib 2durvalumab 2cc-486 2Tretinoin 2Surgical Procedures, Operative 2Standard of Care 2Pemetrexed 2Monatide (IMS 3015) 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Pathologic Complete Response × Observation × Clear all
NCT06743555 2026-04-28

SAVED LUNG

Centre hospitalier de l'Université de Montréal (CHUM)

Phase 1 Not yet recruiting
14 enrolled
Thoracic

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung

NCT07353840 2026-01-20

T-START-CR

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Recruiting
160 enrolled
Lymphoid

Pathologic Complete Response, Lymphoma, T-Cell, Peripheral

NCT04229979 2025-10-01

REGAL

Sellas Life Sciences Group

Phase 3 Active not recruiting
127 enrolled
Other hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡